Company Overview
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company sells and distributes PermeaDerm, a biosynthetic wound matrix and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.
Why Investors Should Care
Revenue has grown at a 106.3% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $71.61M (+11.5% YoY); net profit $-48.59M.
- Trailing 12 Months Year-on-year growth — revenue +4.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 106.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 106.30% |
| 1 Year: | 4.00% |
Stock Price Performance
| 1 Year: | +94.44% |
| 6 Months: | +135.79% |
| 3 Months: | +167.94% |
| 1 Month: | +135.79% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)78.55 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 106.3% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- RSI at 79 suggests overbought conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | RCEL AVITA Medical, Inc. R2KPHARMA | 11.20 | -4.38 | $346.38M | 0.00% | - | - | 106.30% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 269.00K | 1.04M | 1.71M | 2.46M | 3.25M | 3.26M | 3.88M | 3.88M | 5.06M | 5.10M | 8.77M | 10.30M | 7.02M | 7.54M | 8.34M | 9.09M | 10.55M | 11.75M | 13.64M | 11.10M | 15.20M | 19.55M | 18.51M | 18.42M | 17.06M | 17.61M | 19.25M | 21.70M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.83M | 3.47M | 3.19M | 3.30M | 3.52M | - |
| Gross Profit | 37.00K | 798.00K | 1.42M | 1.95M | 2.63M | 2.41M | 3.24M | 3.00M | 4.13M | 4.28M | 6.62M | 8.25M | 5.93M | 5.76M | 6.95M | 7.56M | 8.88M | 9.55M | 11.53M | 9.59M | 13.08M | 16.36M | 15.68M | 14.95M | 13.88M | 14.31M | 15.73M | 17.77M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 27.51M | 26.10M | 23.03M | 24.72M | 24.53M | - |
| Operating Income | -5.06M | -6.30M | -6.68M | -7.49M | -3.66M | -10.59M | -15.41M | -13.02M | -10.21M | -5.63M | -5.99M | -4.70M | -5.95M | -9.49M | -6.36M | -5.75M | -9.91M | -11.16M | -9.31M | -17.21M | -15.62M | -13.81M | -11.83M | -11.15M | -9.15M | -10.41M | -8.80M | -6.86M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -12.10M | -8.11M | -11.33M | -9.69M | -8.57M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.23M | 1.25M | 1.27M | 1.25M | 1.42M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -13.85M | -9.92M | -13.17M | -11.64M | -10.62M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.00K | 4.00K | 15.00K | -17.00K | -11.00K | - |
| Net Income | -5.03M | -6.27M | -6.18M | -7.62M | -3.57M | -10.50M | -15.05M | -12.91M | -10.23M | -5.64M | -6.00M | -4.72M | -5.95M | -9.46M | -6.26M | -5.59M | -9.22M | -10.38M | -8.71M | -18.66M | -15.39M | -16.20M | -13.86M | -9.92M | -13.19M | -11.62M | -10.61M | -7.66M |
| Diluted EPS | -0.38 | -0.44 | -0.34 | -0.41 | -0.19 | -0.53 | -0.71 | -0.60 | 0.48 | -0.26 | 0.26 | 0.19 | 0.24 | 0.38 | 0.25 | 0.22 | -0.37 | -0.41 | -0.34 | -0.73 | -0.60 | -0.62 | -0.53 | -0.38 | -0.46 | -0.38 | -0.35 | -0.25 |
| R&D Expense | 1.97M | 2.02M | 1.81M | 2.07M | 1.82M | 2.31M | 2.50M | 2.54M | 3.37M | 3.36M | 4.11M | 3.97M | 3.39M | 3.62M | 3.06M | 3.80M | 4.59M | 5.08M | 4.39M | 5.19M | 4.89M | 5.43M | 6.28M | 5.12M | 3.75M | - | 5.63M | 5.08M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 929.00K | 5.47M | 14.26M | - | 34.42M | 50.14M | 64.25M | 71.61M |
| Cost of Revenue | - | - | - | - | 6.04M | 7.78M | 9.09M | 12.79M |
| Gross Profit | 383.00K | 4.20M | 11.29M | - | 28.38M | 42.36M | 55.16M | 58.82M |
| Operating Expenses | - | - | - | - | 55.88M | 85.02M | 111.75M | 101.35M |
| Operating Income | -13.84M | -25.53M | -42.68M | - | -27.50M | -42.66M | -56.59M | -42.53M |
| EBITDA | - | - | - | - | -26.05M | -33.54M | -55.30M | -41.23M |
| Interest Expense | - | - | - | - | 16.00K | 1.14M | 5.36M | 5.00M |
| Pretax Income | - | - | - | - | -26.63M | -35.31M | -61.79M | -48.58M |
| Tax Provision | - | - | - | - | 36.00K | 66.00K | 54.00K | 11.00K |
| Net Income | -12.73M | -25.10M | -42.03M | - | -26.66M | -35.38M | -61.84M | -48.59M |
| Diluted EPS | 1.37 | 1.56 | 2.07 | - | -1.07 | -1.40 | -2.39 | -1.74 |
| R&D Expense | 6.26M | 8.00M | 9.16M | 14.82M | 13.86M | 20.82M | 20.36M | 20.84M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 25.78M | 82.46M | - | 116.02M | 98.26M | 111.64M | 79.71M | 56.39M |
| Current Assets | - | - | - | - | - | - | 87.46M | 104.01M | 57.00M | 35.49M |
| Cash & Equivalents | - | - | 20.17M | 73.64M | - | 55.51M | 18.16M | 22.12M | 14.05M | 10.24M |
| Inventory | - | - | - | - | - | - | 2.12M | 5.60M | 7.27M | 6.93M |
| Receivables | - | - | - | - | - | - | 3.52M | 7.66M | 11.79M | 9.09M |
| Total Liabilities | - | - | 4.95M | 10.06M | - | 11.39M | 13.52M | 62.58M | 75.21M | 73.04M |
| Current Liabilities | - | - | 4.48M | 7.71M | - | 9.15M | 10.69M | 13.20M | 20.16M | 62.68M |
| Long Term Debt | - | - | - | - | - | - | - | 39.81M | 42.24M | - |
| Total Debt | - | - | - | - | - | - | 918.00K | 42.41M | 45.98M | 46.05M |
| Total Equity | 3.93M | 14.03M | 20.83M | 72.40M | - | 104.62M | 84.74M | 49.06M | 4.50M | -16.65M |
| Shares Outstanding | - | - | - | - | - | - | 25.21M | 25.68M | 26.35M | 30.57M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -12.96M | -19.25M | -22.75M | - | -19.09M | -38.01M | -48.94M | -31.20M |
| Investing Cash Flow | -365.00K | -1.23M | -847.00K | - | -19.33M | 1.61M | 37.36M | 12.45M |
| Financing Cash Flow | 21.30M | 29.71M | 77.06M | - | 900.00K | 40.37M | 3.51M | 14.94M |
| Capital Expenditure | -365.00K | -1.02M | -590.00K | - | -525.00K | -1.45M | -9.33M | -1.74M |
| Free Cash Flow | -13.32M | -20.27M | -23.34M | - | -19.61M | -39.46M | -58.27M | -32.93M |
| Net Change in Cash | - | - | - | - | -37.52M | 3.97M | -8.07M | -3.81M |
Ratios (Annual)
Figures in %.
| Metric | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 41.2% | 76.8% | 79.2% | - | 82.4% | 84.5% | 85.8% | 82.1% |
| Operating Margin % | -1,489.9% | -466.4% | -299.2% | - | -79.9% | -85.1% | -88.1% | -59.4% |
| Net Margin % | -1,370.8% | -458.6% | -294.7% | - | -77.5% | -70.6% | -96.3% | -67.8% |
| ROE % | -90.8% | -120.5% | -58.1% | - | -31.5% | -72.1% | -1,374.6% | 291.8% |
| ROCE % | - | -119.8% | -57.1% | - | -31.4% | -43.3% | -95.0% | 676.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 4.33% | 1.33M | $13.81M |
| 2 | Blackrock Inc. | 1.84% | 564.95K | $5.85M |
| 3 | Geode Capital Management, LLC | 1.10% | 339.82K | $3.52M |
| 4 | Marshall Wace LLP | 1.10% | 338.39K | $3.50M |
| 5 | AQR Capital Management, LLC | 1.04% | 321.01K | $3.32M |
| 6 | Morgan Stanley | 0.65% | 200.46K | $2.07M |
| 7 | Vanguard Fiduciary Trust Co | 0.59% | 182.40K | $1.89M |
| 8 | NewEdge Advisors, LLC | 0.48% | 148.93K | $1.54M |
| 9 | Macquarie Group Limited | 0.47% | 144.16K | $1.49M |
| 10 | State Street Corporation | 0.42% | 128.98K | $1.33M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RCEL
AVITA Medical (RCEL) Stock Sees Fair Value Lift As Analysts Back RECELL Momentum - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxQWlVSdDhzMWRKWlZaRldpY1B0MEpZWlhCZTZwQTNkRlgzVlEzdEN6c2FrYldabjhhXzU2ZThta3ZYQlAxdjUxNVVoX0t0UjhsTm5nanAxZHRWdHZFVXNnZUVLbG1La0h4TFU0QnZQSWZWMjJKbDhYR3NGWHdsMkxYZWY4dm42ZFd0RGNfcy…
A live webcast will carry AVITA Medical’s Sept. 16 conference discussion. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxQU2F3Q0U4WU1DQXZWMlkxYldlTE9DdVdjMEtrSlYxT1JyZWhnOG5EVDUzMFo5YUhCLUJCdXd5cDhrbTVJN1dRMlpfMFFfMDQ1TjdjUzhQT21FczZFRnowZUpVS3ctdWg0Sm5IS0hUcjA0UFoyTEpSMVR3MHFQZ2FFTTltZF9BQmgyb2ZGc3…
Precision Trading with Avita Medical Inc. (RCEL) Risk Zones - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxQSUEtMXp2dDhRcGxrdTJpdUtvQ09rUGJIaF8xRWlBdXlwQmM1SDdjRHEzMURyVFVZeDJDN28yNzZWa0t5dDZwZ05vaGJISl95NXdRYm84MUhWV3Q3X2FZU1h1anBLN05vYm5hNEw5eDNXMUFIbEF5b29xdWFWOGdfQklfNnRtRVZ2aHF5bU…
564,952 Shares in Avita Medical Inc. $RCEL Bought by BlackRock Inc. - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxOOEQwLXZRdHJIQ1VfUkRLaHJwNy1vZmZYWjVQdjZwZUF1OFZieXA0Sy1tR241WEJOT085RWhBRElZczc3V0ZyTjVRRUtmSjI5d3NPWXRBTFFweUFNa3JKSXczRWM2NHRsVFp4UXFuT2JVb0tneDRLU1pxQ1NJSnVRUnNraFZ2NXp0LXBMN2…
$RCEL stock is up 27% today. Here's what we see in our data. - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxQVHk3eE1wUHRoWnFxWGVnWERvd0NZUGt5S1NXV0VSQW5qU3M5bUptVkQ4dTRlbVNXQWVxWExhcXNGOFpVN0UwbWlKTGtWdjRZc0lEbDFUYk1XMzFGRDY4cXdRT2lNOVRNazNNUG13NkJKZFo0dmFzc2wtcE1TbzBDNWZFbV84VEZ6aDFYd1…
AVITA Medical (RCEL) Stock Fair Value Rises After PermeaDerm Data And Analyst Target Increases - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxQdWlrVXJvbEFRN1l4TXV5VUQ5dElYemhRVVVCUXMzRk0wV0pqakIxYWtGSkpxSUI4c2Q4em1rMjQtMGRGaDFpUGhuMUFEN09DQjh1YnFRRzB0NV8tWWViaERaUTRZQ1JjSmgtVkxiOGhRUnhFTlg0VlpkbVhhWjFrYjRQYWYtdTB5VVBMRG…
RCEL — Frequently Asked Questions
What is the current share price of AVITA Medical, Inc. (RCEL)?
As of 2026-09-07 16:24 PDT, AVITA Medical, Inc. (RCEL) trades at $11.20 on NasdaqCM. Its 52-week range is $3.27 to $11.20.
What is the market capitalisation of RCEL?
AVITA Medical, Inc. (RCEL) has a market capitalisation of $346.38M on NasdaqCM.
What is the P/E ratio of RCEL?
RCEL trades at a trailing price-to-earnings (P/E) ratio of -4.38. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is -10.32.
Is RCEL a good stock to buy?
This page provides a data-driven analysis of AVITA Medical, Inc. (RCEL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.